Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

April 15, 2019

Study Completion Date

November 18, 2019

Conditions

Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG

Cabozantinib 40 MG

To be taken orally once daily

DRUG

Erlotinib 100Mg Tab

To be taken orally once daily

Trial Locations (2)

Indiana University Health Hospital, Indianapolis

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis